Important Updates on COVID-19

As the COVID-19 (coronavirus) pandemic continues to evolve around the world, Otsuka stands united with our global community to navigate this fast moving and complex healthcare event.

Read the full statement

Otsuka is Lead, Founding Sponsor of PBS’ WELL BEINGS Youth Mental Health Project, Featuring Ken Burns Documentary Series

New Multi-year Public Health Campaign and Documentary Focus on Mental Health Issues PRINCETON, N.J. – May 21, 2020 – Otsuka America Pharmaceutical, Inc., announces that the company is the lead, founding sponsor of the WELL BEINGS Youth Mental Health Project, a multi-year, public health campaign launched by WETA, the flagship public broadcasting station in the nation’s capital.  The sponsorship also includes the future PBS documentary series Hiding in Plain Sight: Our Mental Health Crisis (working title), executive-produced by award-winning filmmaker Ken Burns, produced and directed by Ewers Brothers Productions, which will focus on mental health issues ranging from anxiety, depression, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, addiction, suicide and more. WELL BEINGS addresses the critical health needs of Americans through broadcast content, original digital content, and impactful local events. The WELL BEINGS campaign debuts with the YOUTH MENTAL HEALTH PROJECT, featuring a variety of educational information and resources emphasizing mental health needs and amplifying the voices of youth in America. Diverse groups from around the country will participate in the program, including patients, families, caregivers, teachers, medical and mental health professionals, social service agencies, private foundations, filmmakers, corporations and media sponsors. “Public media is uniquely situated to convene expert partners, reach wide audiences, and create cross-platform content on urgent public issues.  The mental health crisis in this country is critically important, and we have the opportunity to create a national conversation on this topic as well as provide robust resources,” said Sharon Percy Rockefeller, president and CEO of WETA Washington, D.C. “Mental health issues are particularly acute for young people now, but they are also showing us new ways to intervene and provide care and assistance to those with the greatest needs. By listening to their peers, removing the stigma associated with these illnesses, and helping guide those in need to resources, young people are inspiring all who are seeking new approaches and changing how Americans think about mental health issues.” The Hiding in Plain Sight: Our Mental Health Crisis (working title) documentary is intended for national broadcast on public media, as well as international distribution. The film will explore how young people are addressing their mental health needs and the impact of mental health stigma and stress on today’s youth, as well as advances in research and therapy. The four-hour film, produced and directed by Erik Ewers and Christopher Loren Ewers of Ewers Brother Productions, will look at the experiences of young people who live with mental health conditions and focus on the importance of awareness and compassion. This film will shine a clear light on what life is like for these young people as well as for the parents, teachers, friends and healthcare providers in their lives. The documentary will be accompanied by an expansive outreach, education, and social media campaign with a strong focus on direct engagement of youth and communities.            “As a leader in mental health, Otsuka is honored to be the lead, founding sponsor of the WELL BEINGS Youth Mental Health Project and documentary, executive-produced by world-renowned master storyteller, Ken Burns,” said Kabir Nath, president and CEO, Otsuka North America Pharmaceutical Business. “Now more than ever, we must work collectively to provide a ‘Voice’ to the millions of people, many of them our youth, who live with mental illness. Otsuka’s mission is to defy limitation, so that others can too, and this important film and surrounding campaign has the potential to be the catalyst to truly make a difference.” The WELL BEINGS Youth Mental Health Project will also feature a 24-city tour where teachers, counselors and youth can discuss topics around mental health today and review resources and information on best practices, including youth-focused engagement, training and support systems. The tour will be virtual and/or in-person, depending on the market and current public health concerns. For more information about the WELL BEINGS campaign, visit WellBeings.org or follow @WellBeingsOrg on Instagram, Facebook, or Twitter, and join the conversation with #WellBeings. About WETA WETA is the leading public broadcaster in the nation’s capital, serving Virginia, Maryland and the District of Columbia with educational initiatives and with high-quality programming on television, radio and digital. WETA Washington, D.C., is the second largest producing-station of new content for public television in the United States, with news and public affairs programs including PBS NEWSHOUR and WASHINGTON WEEK; films by Ken Burns such as COUNTRY MUSIC, KEN BURNS PRESENTS THE GENE: AN INTIMATE HISTORY and THE ROOSEVELTS: AN INTIMATE HISTORY; series and documentaries by Dr. Henry Louis Gates, Jr., including FINDING YOUR ROOTS WITH HENRY LOUIS GATES, JR. (Seasons 3-6) and RECONSTRUCTION: AMERICA AFTER THE CIVIL WAR; and performance specials including THE KENNEDY CENTER MARK TWAIN PRIZE and THE LIBRARY OF CONGRESS GERSHWIN PRIZE FOR POPULAR SONG. More information on WETA and its programs and services is available at www.weta.org. On social media, visit www.facebook.com/wetatvfm on Facebook or follow @WETAtvfm on Twitter. About Otsuka Pharmaceutical Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.  In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.  Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology and cardiology, using cutting-edge technology to address unmet healthcare needs.  Otsuka’s most recently approved product in the U.S. is the first-ever treatment for autosomal dominant polycystic kidney disease, a  genetic disorder in which fluid-filled cysts develop in the kidneys over time, often leading to kidney failure. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13 billion in 2019. All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/. Media Contacts Otsuka In U.S.                                                                                             Robert Murphy
Corporate Communications
Otsuka America Pharmaceutical, Inc.
robert.murphy@otsuka-us.com
+1 609 249 7262                                                       Otsuka in Japan Jeffrey Gilbert (Outside the U.S.)
Leader, Pharmaceutical PR  
Otsuka Pharmaceutical, Co., Ltd.
gilbert.jeffrey@otsuka.co.jp
+81 3 6361 7379, +81 80 8728 6039